1. Home
  2. BIRD vs HBIO Comparison

BIRD vs HBIO Comparison

Compare BIRD & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Allbirds Inc.

BIRD

Allbirds Inc.

HOLD

Current Price

$3.92

Market Cap

26.2M

ML Signal

HOLD

Logo Harvard Bioscience Inc.

HBIO

Harvard Bioscience Inc.

HOLD

Current Price

$6.20

Market Cap

24.9M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
BIRD
HBIO
Founded
2015
1901
Country
United States
United States
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Laboratory Analytical Instruments
Sector
Consumer Discretionary
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
26.2M
24.9M
IPO Year
2021
2000

Fundamental Metrics

Financial Performance
Metric
BIRD
HBIO
Price
$3.92
$6.20
Analyst Decision
Hold
Buy
Analyst Count
1
2
Target Price
$8.00
$18.00
AVG Volume (30 Days)
396.4K
25.0K
Earning Date
05-07-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
20.22
N/A
EPS
N/A
N/A
Revenue
$152,466,000.00
$116,176,000.00
Revenue This Year
N/A
$4.77
Revenue Next Year
$35.12
$8.55
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.15
$0.38
52 Week High
$24.31
$7.50

Technical Indicators

Market Signals
Indicator
BIRD
HBIO
Relative Strength Index (RSI) 41.81 54.37
Support Level $3.79 $6.05
Resistance Level $3.93 $6.85
Average True Range (ATR) 0.37 0.44
MACD 0.03 0.01
Stochastic Oscillator 20.00 66.23

Price Performance

Historical Comparison
BIRD
HBIO

About BIRD Allbirds Inc.

Allbirds Inc is a lifestyle brand that innovates with naturally derived materials to make footwear and apparel products in a better way, while treading lighter on the planet. Its primary source of revenue is from sales of shoes and apparel products. The majority of the revenue is derived from United States.

About HBIO Harvard Bioscience Inc.

Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.

Share on Social Networks: